Bahram Valamehr sold $13k of FATE
President and CEO at FATE THERAPEUTICS INC. 8,705 shares at an average of $1.54, traded Jan 10, 2025, filed Jan 13, 2025.
Score components
- +25RoleCEO
- 0Trade size$13k at market
- 0Share of holdings soldSold 2.4% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-004814, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 10, 2025 | SOpen-market sale Common Stock | -8,705 | $1.54 | $13k | 349,364 | Jan 13, 2025 |
Related signals
Other insiders at FATE THERAPEUTICS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | FATE THERAPEUTICS INC | Jerome Charles Bressi See Remarks | $9,269 5,980 shares | -2% | |
| 30Weak | FATE THERAPEUTICS INC | Cindy Tahl See Remarks | $8,764 5,654 shares | -2% | |
| 35Weak | FATEbuy FATE THERAPEUTICS INC | Redmile Group, LLC director, owner | $669k 397,964 shares | +3% | |
| 34Weak | FATEsell FATE THERAPEUTICS INC | Redmile Group, LLC director, owner | $574k 341,633 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.